Dermatology · Garland, TX
NPI
1700088804
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1919 S Shiloh Rd, Suite 300
Garland, TX, 75042
Phone (972) 278-4992
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
22,336 services
Medicare patients, 2024
1,767
Average age 75
Drug cost, 2024
$1.5M
4,501 prescriptions
Company payments, 2025
$150K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin F Kia was code 17003 (destruction skin lesion), 8,587 times for 1,069 patients. In total Kevin F Kia billed 22,336 services in 104 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 8,587 | 1,069 | $4.23 | $36K |
| 99214 Office E&M - Established | Office | 2,891 | 1,336 | $76.43 | $221K |
| 17004 Destruction Skin Lesion | Office | 2,016 | 945 | $111.40 | $225K |
| 17110 Destruction Skin Lesion | Office | 1,870 | 1,121 | $82.71 | $155K |
| 17000 Destruction Skin Lesion | Office | 1,860 | 1,113 | $35.32 | $66K |
| 11102 Skin Biopsy | Office | 1,092 | 783 | $57.98 | $63K |
| 99213 Office E&M - Established | Office | 1,011 | 649 | $63.56 | $64K |
| 96910 Skin | Office | 425 | 28 | $52.07 | $22K |
| 13121 Wound Repair - All Levels | Office | 274 | 214 | $329.65 | $90K |
| 11103 Skin Biopsy | Office | 260 | 178 | $38.48 | $10K |
| 13132 Wound Repair - All Levels | Office | 246 | 195 | $367.17 | $90K |
| 11603 Skin Lesion Excision | Office | 210 | 159 | $107.95 | $23K |
| 99203 Office E&M - New | Office | 145 | 145 | $70.55 | $10K |
| 99204 Office E&M - New | Office | 126 | 126 | $65.56 | $8,261 |
| 11643 Skin Lesion Excision | Office | 123 | 103 | $124.86 | $15K |
By year: 2022 $1.1M for 20,190 services; 2023 $1.2M for 22,151 services; 2024 $1.2M for 22,336 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kevin F Kia prescribed most often to Medicare patients was Minocycline Hcl, with 996 prescriptions and refills. In total Kevin F Kia wrote 4,501 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Minocycline Hcl Generic | 996 | 996 | 788 | $8,764 |
| Ketoconazole Generic | 524 | 567 | 234 | $7,202 |
| Clobetasol Propionate Generic | 439 | 461 | 249 | $20K |
| Triamcinolone Acetonide Generic | 371 | 426 | 267 | $3,214 |
| Betamethasone Dipropionate Generic | 260 | 271 | 164 | $11K |
| Tacrolimus Generic | 255 | 260 | 171 | $16K |
| Metronidazole Generic | 103 | 107 | 60 | $4,446 |
| Gabapentin Generic | 86 | 107 | 34 | $1,577 |
| Mycophenolate Mofetil Generic | 85 | 101 | 28 | $5,522 |
| Fluocinonide Generic | 82 | 88 | 50 | $3,169 |
| Mupirocin Generic | 67 | 67 | 57 | $604 |
| Cephalexin Generic | 64 | 64 | 48 | $308 |
| Valacyclovir Valacyclovir Hcl | 63 | 103 | 40 | $1,779 |
| Dupixent Pen Dupilumab | 62 | 62 | 13 | $233K |
| Doxycycline Hyclate Generic | 56 | 64 | 34 | $942 |
Brand drugs: 303 claims; generic drugs: 4,198 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin F Kia $150K ($150K in general payments such as food, travel and fees) from 18 companies. The largest payer was Galderma Laboratories, L.P. with $85K.
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. GALD.SW | 103 | $85K |
| Abbvie Inc. ABBV | 69 | $62K |
| Genzyme Corporation SNY | 19 | $665 |
| Endo USA, Inc. | 1 | $420 |
| UCB, Inc. UCB.BR | 8 | $344 |
| Incyte Corporation INCY | 5 | $288 |
| Regeneron Healthcare Solutions, Inc. REGN | 18 | $236 |
| Lilly USA, LLC LLY | 2 | $181 |
| Organon LLC OGN | 14 | $169 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.